Dr. Ted Lain sits down with board-certified pediatric dermatologist Dr. Nnenna Agim to discuss the toddler indication for roflumilast cream (Zoryve) and how non-steroidal topicals are changing the treatment landscape for atopic dermatitis, psoriasis, and seborrheic dermatitis in children.

In this episode of the Science of Skin Podcast, Dr. Agim shares her real-world clinical experience using roflumilast cream 0.05% (ages 2-5) and 0.15% (ages 6+) as a steroid-sparing alternative for pediatric eczema, explaining why more families are requesting non-steroidal options from the start of treatment. The conversation covers:

• Why roflumilast (Zoryve) is safe to use on any body surface, including the face and skin folds
• Managing parent expectations and proper dosing to avoid overuse
• The importance of pairing roflumilast with ceramide-rich, fragrance-free moisturizers like CeraVe, La Roche-Posay, and Vaseline
• How roflumilast compares to crisaborole (Eucrisa) and topical corticosteroids in tolerability
• Treating psoriasis and seborrheic dermatitis in children with roflumilast foam and cream
• Skin barrier repair, ceramide production, and the role of the acid mantle in atopic dermatitis
• Caring for textured hair and scalp conditions in pediatric patients
• Real patient outcomes and quality-of-life improvements with Zoryve

This episode is sponsored by Arcutis Biotherapeutics and is part of an ongoing series exploring roflumilast formulation science. Don't miss the related episode on roflumilast's formulation with Dr. Chris Bunick.

Learn more about the Science of Skin Summit (Austin, TX) and the new Science of Skin Longevity Summit (Scottsdale, AZ, Feb 2027) at scienceofskinsummit.com.

🔔 Subscribe and leave a 5-star rating to support the show!

Disclaimer: This podcast is not intended to provide diagnosis, treatment, or medical advice. Content provided in this podcast is for educational purposes only. Please consult with a physician regarding any health-related diagnosis or treatment.

See omnystudio.com/listener for privacy information.